Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

August 5th 2022

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

Future Directions in Metastatic Uveal Melanoma Treatment

August 5th 2022

Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

August 4th 2022

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma

July 29th 2022

Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.

Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma

July 29th 2022

Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Dr. Sznol on the Significance of the Relatlimab/Nivolumab Approval in Metastatic Melanoma

July 26th 2022

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

Immune Checkpoint Inhibitors at ASCO: Long-term Efficacy Data Mount

July 25th 2022

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

Relatlimab Plus Nivolumab Approaches EU Approval for Advanced Melanoma With PD-L1 of <1%

July 23rd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of the fixed-dose combination of nivolumab and relatlimab for the frontline treatment of adult and adolescents who are 12 years of age or older with advanced melanoma and a tumor cell PD-L1 expression of less than 1%.

Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma

July 22nd 2022

Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.

Overview of Metastatic Uveal Melanoma

July 22nd 2022

Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.

Basal Cell Carcinoma Clinical Pearls

July 18th 2022

Drs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.

Metastasis Patterns of Basal Cell Carcinoma

July 18th 2022

A look at how common metastatic basal cell carcinoma is in clinical practice and when to consider frontline immunotherapy.

AR Signaling Plays a Role in Diminished Response to BRAF/MEK Inhibitors

July 15th 2022

Major pathological response and recurrence-free survival rates were improved in women vs men with melanoma who received BRAF/MEK inhibitor therapy in the neoadjuvant setting.

Expanding Opportunities for Real-World Evidence in Oncology

July 7th 2022

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Safety of Cemiplimab for Basal Cell Carcinoma

July 7th 2022

Experts review the safety and toxicity data of anti-PD-1 antibody agent cemiplimab for basal cell carcinoma treatment.

Dr. Sullivan on the Examination of Tebentafusp in Uveal Melanoma

July 6th 2022

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Monitoring Strategies for Basal Cell Carcinoma

July 6th 2022

Shahab Babakoohi, MD, describes his monitoring strategies for patients with basal cell carcinoma.

Systemic Therapy Options for Basal Cell Carcinoma

July 1st 2022

Dr Jennifer Atlas leads a conversation on systemic therapy options in basal cell carcinoma with a review of clinical trial data.

Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic Melanoma

June 28th 2022

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.